Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2016, Vol. 10 Issue (2) : 204-211     DOI: 10.1007/s11684-016-0443-1
CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes
Jiangnan Liu1,2,Bin Yi1,2,Zhe Zhang1,2,Yi Cao1,*()
1. Laboratory of Molecular and Experimental Pathology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China
2. Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming 650223, China
Download: PDF(1013 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate epitope (glycotope) functionally involved in blood spread and liver metastasis of cancer cells by mediating the adhesion of cancer cells to endothelial cells and hepatocytes, respectively. CD176 could be a promising target for antitumor immunotherapy. We applied B lymphocytes obtained from mice immunized with CD176 antigen and constructed a phage display library. A positive clone of CD176 single-chain variable antibody fragment (scFv) was successfully screened from this library. The CD176 scFv was expressed in Escherichia coli and purified. The purified scFv can bind to the natural CD176 expressed on the surface of cancer cells. Furthermore, the CD176 scFv inhibits the adhesion of CD176+ cancer cells to endothelial cells and hepatocytes. This CD176 scFv provides a basis for future development of recombinant CD176-specific antibodies that can be used in therapeutic application.

Keywords CD176      Thomsen-Friedenreich antigen      scFv      cancer      therapy      adhesion      metastasis     
Corresponding Authors: Yi Cao   
Just Accepted Date: 29 March 2016   Online First Date: 18 April 2016    Issue Date: 27 May 2016
URL:     OR
Fig.1  The binding ability of phage display CD176 scFv to antigens. The displayed CD176 scFv against CD176 (TF-PAA) (A) and aGP (B) was detected by ELISA. CD176 (TF-PAA) and aGP were coated on 96-plates (200 ng/well). M13KO7 helper phage was used as a negative control and CD176 mAb (IgM) as a positive control (mean±SD, n = 3).
Fig.2  Construction, expression, and purification of the CD176 scFv. (A) Expression of the CD176 scFv fusion protein was detected by SDS-PAGE (lines 1?4). Lines 1 and 2 were the suspense and sediment of lysis after induction with IPTG, respectively. Lines 3 and 4 were the suspense and sediment of lysis without IPTG induction, respectively. PET32a(+) was used as the control (lines 5?8). Lines 5 (suspense) and 6 (sediment) showed expressed results of PET32a(+) vector with IPTG induction, whereas lines 7 (suspense) and 8 (sediment) showed expressed results without IPTG induction. (B) Line 1 showed the CD176 scFv fusion protein after nickel-affinity purification; lines 2?5 showed the CD176 scFv fusion protein digested by enterokinase in 16, 24, 36, and 48 h, respectively. (C) The digested protein sample (scFv) was purified by IEC and yielded 11 protein fractions. All fractions were subjected to SDS-PAGE. (D) The result of the highest fraction, as demonstrated by SDS-PAGE. Line 1 is the fusion protein before purification and line 2 is the digested protein after purification.
Fig.3  Biological characteristics of the CD176 scFv. The binding of the purified CD176 scFv to the natural CD176 on the surfaces of cancer cells was shown (A and B). (A) Flow cytometry analysis showed that the scFv bound to KG1 cells (middle) compared with the controls [incubation with BSA (left) and irrelevant scFv (right)]. (B) The scFv reacted with CD176+ cell lines by immunofluorescence staining, and a CD176 mAb (IgM) was used as the positive control. The adhesion of CD176+ cancer cells to HUVEC and HL-7702 was inhibited by the CD176 scFv (C?E). (C) The adhesion of FITC-labeled SGC7901 cells to HUVEC was suppressed by the CD176 scFv (scFv) at different incubation times compared with the negative control (control). The inhibition effects of the CD176 scFv were semiquantitatively analyzed by luciferase assay (D, E). The adhesion of SW480 and SGC7901 to HUVEC (D) and HL-7702 (E) were inhibited significantly by the CD176 scFv compared with negative controls (control scFv and no treatment). y-axis is mean intensity fluorescence (mean±SD, n = 4).
1 Little M, Kipriyanov SM, Le Gall F, Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol Today 2000; 21(8): 364–370
doi: 10.1016/S0167-5699(00)01668-6 pmid: 10916138
2 Dübel S. Recombinant therapeutic antibodies. Appl Microbiol Biotechnol 2007; 74(4): 723–729
doi: 10.1007/s00253-006-0810-y pmid: 17225094
3 Goletz S, Cao Y, Danielczyk A, Ravn P, Schoeber U, Karsten U. Thomsen-Friedenreich antigen: the “hidden” tumor antigen. Adv Exp Med Biol 2003; 535: 147–162
doi: 10.1007/978-1-4615-0065-0_10 pmid: 14714894
4 Cao Y, Merling A, Karsten U, Schwartz-Albiez R. Expression of Thomsen-Friedenreich-related carbohydrate antigens on human leukemia cells. In: Mason D et al. Leucocyte Typing VII. Oxford: Oxford University Press, 2002; 204–205
5 Cao Y, Stosiek P, Springer GF, Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 1996; 106(2): 197–207
doi: 10.1007/BF02484401 pmid: 8877380
6 Lin WM, Karsten U, Goletz S, Cheng RC, Cao Y. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol 2011; 92(2): 97–105
doi: 10.1111/j.1365-2613.2010.00747.x pmid: 21070402
7 Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 2001; 61(12): 4851–4857
pmid: 11406562
8 Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF, Schlag PM. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 1995; 76(10): 1700–1708
doi: 10.1002/1097-0142(19951115)76:10<1700::AID-CNCR2820761005>3.0.CO;2-Z pmid: 8625037
9 Cao Y, Merling A, Karsten U, Goletz S, Punzel M, Kraft R, Butschak G, Schwartz-Albiez R. Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int J Cancer 2008; 123(1): 89–99
doi: 10.1002/ijc.23493 pmid: 18398838
10 Yi B, Zhang M, Schwartz-Albiez R, Cao Y. Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells. Int J Oncol 2011; 38(6): 1565–1573
pmid: 21455576
11 Yi B, Zhang Z, Zhang M, Schwartz-Albiez R, Cao Y. CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia. Oncol Rep 2013; 30(4): 1841–1847
pmid: 23900643
12 Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228(4705): 1315–1317
doi: 10.1126/science.4001944 pmid: 4001944
13 Chan CE, Lim AP, MacAry PA, Hanson BJ. The role of phage display in therapeutic antibody discovery. Int Immunol 2014; 26(12): 649–657
doi: 10.1093/intimm/dxu082 pmid: 25135889
14 McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348(6301): 552–554
doi: 10.1038/348552a0 pmid: 2247164
15 Larsen SA, Meldgaard T, Lykkemark S, Mandrup OA, Kristensen P. Selection of cell-type specific antibodies on tissue-sections using phage display. J Cell Mol Med 2015; 19(8): 1939–1948
doi: 10.1111/jcmm.12568 pmid: 25808085
16 Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23(9): 1126–1136
doi: 10.1038/nbt1142 pmid: 16151406
17 Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23(9): 1105–1116
doi: 10.1038/nbt1126 pmid: 16151404
18 Karsten U, Butschak G, Cao Y, Goletz S, Hanisch FG. A new monoclonal antibody (A78-G/A7) to the Thomsen-Friedenreich pan-tumor antigen. Hybridoma 1995; 14(1): 37–44
doi: 10.1089/hyb.1995.14.37 pmid: 7539400
19 Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273(34): 21769–21776
doi: 10.1074/jbc.273.34.21769 pmid: 9705314
20 Schirrmann T, Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 2010; 651: 177–209
doi: 10.1007/978-1-60761-786-0_11 pmid: 20686967
21 Yuasa N, Zhang W, Goto T, Sakaue H, Matsumoto-Takasaki A, Kimura M, Ohshima H, Tsuchida Y, Koizumi T, Sakai K, Kojima T, Yamamoto K, Nakata M, Fujita-Yamaguchi Y. Production of anti-carbohydrate antibodies by phage display technologies: potential impairment of cell growth as a result of endogenous expression. J Biol Chem 2010; 285(40): 30587–30597
doi: 10.1074/jbc.M110.107284 pmid: 20667829
22 Arjmand R, Fard SS, Saberi S, Tolouei S, Khamesipour A, Hejazi SH. Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Adv Biomed Res 2015; 4(1): 128
doi: 10.4103/2277-9175.158068 pmid: 26261830
23 Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some. Front Immunol 2015; 6: 127
doi: 10.3389/fimmu.2015.00127 pmid: 25859247
24 Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, Boerman OC. Theranostic applications of antibodies in oncology. Mol Oncol 2014; 8(4): 799–812
doi: 10.1016/j.molonc.2014.03.010 pmid: 24725480
25 Rabu C, McIntosh R, Jurasova Z, Durrant L. Glycans as targets for therapeutic antitumor antibodies. Future Oncol 2012; 8(8): 943–960
doi: 10.2217/fon.12.88 pmid: 22894669
26 Fujita-Yamaguchi Y. Production of single-chain variable-fragments against carbohydrate antigens. Antibodies (Basel) 2014; 3(1): 155–168
doi: 10.3390/antib3010155
27 Ravn P, Stahn R, Danielczyk A, Faulstich D, Karsten U, Goletz S. The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs. Cancer Immunol Immunother 2007; 56(9): 1345–1357
doi: 10.1007/s00262-007-0292-5 pmid: 17310382
28 Yuasa N, Koyama T, Fujita-Yamaguchi Y. Purification and refolding of anti-T-antigen single chain antibodies (scFvs) expressed in Escherichia coli as inclusion bodies. Biosci Trends 2014; 8(1): 24–31
doi: 10.5582/bst.8.24 pmid: 24647109
29 Cao Y, Schlag PM, Karsten U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch 1997; 431(3): 159–166
doi: 10.1007/s004280050083 pmid: 9334836
[1] FMD-16209-of-CY_suppl_1 Download
[1] Yiming Ma,Ting Xiao,Quan Xu,Xinxin Shao,Hongying Wang. iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer[J]. Front. Med., 2016, 10(3): 278-285.
[2] Aining Xu,Lin Cheng. Chemical transdifferentiation: closer to regenerative medicine[J]. Front. Med., 2016, 10(2): 152-165.
[3] Wei Lu,Qingzhang Zhou,Hao Yang,Hao Wang,Yexing Gu,Qi Shen,Jinglun Xue,Xiaoyan Dong,Jinzhong Chen. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX[J]. Front. Med., 2016, 10(2): 212-218.
[4] Xinsen Xu,Kai Qu,Qing Pang,Zhixin Wang,Yanyan Zhou,Chang Liu. Association between telomere length and survival in cancer patients: a meta-analysis and review of literature[J]. Front. Med., 2016, 10(2): 191-203.
[5] Alexandra Urman,H. Dean Hosgood. Curbing the burden of lung cancer[J]. Front. Med., 2016, 10(2): 228-232.
[6] Chunxiao Li,Haijuan Wang,Feng Lin,Hui Li,Tao Wen,Haili Qian,Qimin Zhan. Bioinformatic exploration of MTA1-regulated gene networks in colon cancer[J]. Front. Med., 2016, 10(2): 178-182.
[7] Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li. Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo[J]. Front. Med., 2016, 10(1): 41-51.
[8] Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
[9] Aixiu Qiao,Feng Gu,Xiaojing Guo,Xinmin Zhang,Li Fu. Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications[J]. Front. Med., 2016, 10(1): 33-40.
[10] Dan Wu,Qingxun Hu,Yizhun Zhu. Therapeutic application of hydrogen sulfide donors: the potential and challenges[J]. Front. Med., 2016, 10(1): 18-27.
[11] Hualiang Lin,Bofu Ning,Jihua Li,Guangqiang Zhao,Yunchao Huang,Linwei Tian. Temporal trend of mortality from major cancers in Xuanwei, China[J]. Front. Med., 2015, 9(4): 487-495.
[12] Yinyin Xie,Yuanliang Zhang,Lu Jiang,Mengmeng Zhang,Zhiwei Chen,Dan Liu,Qiuhua Huang. Disabled homolog 2 is required for migration and invasion of prostate cancer cells[J]. Front. Med., 2015, 9(3): 312-321.
[13] Yi Cao. Environmental pollution and DNA methylation: carcinogenesis, clinical significance, and practical applications[J]. Front. Med., 2015, 9(3): 261-274.
[14] Daniel Wai-Hung Ho,Alan Ka-Lun Kai,Irene Oi-Lin Ng. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma[J]. Front. Med., 2015, 9(3): 322-330.
[15] Felice Ho-Ching Tsang,Sandy Leung-Kuen Au,Lai Wei,Dorothy Ngo-Yin Fan,Joyce Man-Fong Lee,Carmen Chak-Lui Wong,Irene Oi-Lin Ng,Chun-Ming Wong. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility[J]. Front. Med., 2015, 9(3): 331-343.
Full text